Renovaro Biosciences develops advanced cell, gene, and immunotherapy platforms for oncology. It focuses on diagnostics and therapies for cancer treatment, utilizing AI and liquid biopsies.

Enochian Biosciences, Inc.

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

COM:ENOCHIANBIO

Renovaro Biosciences

Last Close

0.70

04/08 19:58

Market Cap

45.38M

Beta: -

Volume Today

87.29K

Avg: -

name

homepage url

country

employee count

sector

industry

monthly webtraffic

monthly webtraffic growth

Description

peer of

competitor of

Metrics